Buscar

Estamos realizando la búsqueda. Por favor, espere...

Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry

Abstract: Aim: To analyze the clinical effect of continuous subcutaneous insulin infusion (CSII) in type 1 diabetes mellitus (T1D) patients in the Spanish real-world scenario. Methods: All T1D patients on CSII registered in the SPAnish Insulin Pump (SPAIP) registry were included. The primary efficacy outcome was change in HbA1c during follow-up. Secondary efficacy outcomes included: insulin pump indications, diabetes complication rates, insulin and pump use, and continuous glucose monitoring (CGM) glycometrics. Patient data were typed through the web-based SPAIP registry. Results: Data from 2979 T1D patients treated with CSII were analyzed. The median age was 44 years (interquartile range [IQR] 34?52 years), and T1D duration was 27 years (IQR 18?35 years). The median duration of CSII therapy was 6 years (IQR 3?10 years). The main indications for treatment were suboptimal glycemic control (33.8%), hypoglycemia (22.1%), and increased glycemic variability (18.8%). Glycated hemoglobin decreased by 6?mmol/mol (95% CI, ?5 to ?6?mmol/mol, P?

 Fuente: Diabetes Technology and Therapeutics, 2022, 24(12), 898-906

 Editorial: Mary Ann Liebert

 Año de publicación: 2022

 Nº de páginas: 9

 Tipo de publicación: Artículo de Revista

 DOI: 10.1089/dia.2022.0207

 ISSN: 1520-9156,1557-8593

 Url de la publicación: https://doi.org/10.1089/dia.2022.0207

Autoría

MORENO-FERNÁNDEZ, JESÚS

CHICO, ANA

MARTÍNEZ-BROCCA, MARÍA ASUNCIÓN

BEATO-VÍBORA, PILAR ISABEL

VIDAL, MERCÉ

MARIA PIEDRA LEON

QUIRÓS, CARMEN

MUÑOZ-RODRÍGUEZ, JOSÉ RAMÓN